International Conference on Harmonisation; Draft Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; Availability, 6697-6698 [05-2418]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices
V. Electronic Access
Copies of the guidance document
entitled ‘‘Guidance for Industry: Animal
Drug Sponsor Fees Under the Animal
Drug User Fee Act’’ may be obtained
from the CVM home page (https://
www.fda.gov/cvm) and from the
Division of Dockets Management Web
site (https://www.fda.gov/ohrms/dockets/
default.htm).
Dated: January 28, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–2417 Filed 2–7–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D–0030]
Draft Guidance for Industry on Clinical
Lactation Studies—Study Design, Data
Analysis, and Recommendations for
Labeling; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Clinical Lactation
Studies—Study Design, Data Analysis,
and Recommendations for Labeling.’’
This guidance discusses agency
recommendations on how and when to
conduct clinical lactation studies and
how to assess the influence of drugs or
biologic products on lactation. The goals
of this guidance are to provide the basic
framework for designing, conducting,
and analyzing clinical lactation studies
and to stimulate further study and
research to assist in rational
therapeutics for lactating patients.
DATES: Submit written or electronic
comments on the draft guidance by
April 11, 2005. General comments on
agency guidance documents are
welcome at any time.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, or the Office of
Communications, Training, and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), 1401 Rockville Pike,
Rockville, MD 20852–1448. Send one
self-addressed adhesive label to assist
that office in processing your requests.
VerDate jul<14>2003
18:12 Feb 07, 2005
Jkt 205001
Submit written comments on the draft
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. The
guidance may also be obtained from
CBER by mail by calling 1–800–835–
4709 or 301–827–1800. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance document.
FOR FURTHER INFORMATION CONTACT:
Kathleen Uhl, Center for Drug
Evaluation and Research (HFD–020),
Food and Drug Administration, 5515
Security Lane, Rockville, MD 20852,
301–443–5157, or Toni M. Stifano,
Center for Biologics Evaluation and
Research (HFM–600), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852, 301–827–6190.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Clinical Lactation Studies—Study
Design, Data Analysis, and
Recommendations for Labeling.’’ This
guidance is intended to provide
recommendations to sponsors and
investigators on how to design, conduct,
and assess studies investigating the
influence of lactation on maternal
pharmacokinetics (PK), and where
appropriate, the pharmacodynamics of
drugs or biologic products, the extent of
drug transfer into breast milk, and the
effects of drugs on milk production and
composition. Clinical lactation studies
are usually not conducted during the
development of most products and
lactating women are actively excluded
from trials. Consequently, at the time of
a drug’s initial marketing, there are
seldom meaningful human data on the
appropriate dosage and frequency of
administration during lactation. Even
after years of marketing, data in product
labels regarding lactation rarely provide
more information for appropriate
prescribing in lactation than what was
available at the time of initial marketing.
The information in this guidance is
intended to promote an increase in the
amount of useful data concerning how
drug kinetics are affected by lactation,
the extent of drug transfer into breast
milk, and the effects of drugs on milk
production and composition. Topics
covered include study design, data
analysis, labeling, and considerations
for future research. The agency
recommends using this guidance in
conjunction with other pharmacological
and clinical literature on the design,
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
6697
conduct, and interpretation of PK
studies. Because the conduct of studies
in lactating women and their breast-fed
infants requires specialized knowledge
in a variety of areas, investigators
designing such studies are encouraged
to obtain advice from experts in fields
including obstetrics, pediatrics,
pharmacology, clinical pharmacology,
pharmacometrics, statistics, and other
applicable disciplines.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the agency’s current thinking
on this topic. It does not create or confer
any rights for or on any person and does
not operate to bind FDA or the public.
An alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments on the draft guidance. Submit
a single copy of electronic comments or
two paper copies of any mailed
comments, except that individuals may
submit one paper copy. Comments are
to be identified with the docket number
found in brackets in the heading of this
document. The draft guidance and
received comments are available for
public examination in the Division of
Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet
may obtain the document at either http:/
/www.fda.gov/cder/guidance/index.htm
or https://www.fda.gov/ohrms/dockets/
default.htm.
Dated: February 1, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–2416 Filed 2–7–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D–0022]
International Conference on
Harmonisation; Draft Guidance on S8
Immunotoxicity Studies for Human
Pharmaceuticals; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
E:\FR\FM\08FEN1.SGM
Notice.
08FEN1
6698
Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘S8 Immunotoxicity Studies for Human
Pharmaceuticals.’’ The draft guidance
was prepared under the auspices of the
International Conference on
Harmonisation of Technical
Requirements for Registration of
Pharmaceuticals for Human Use (ICH).
The draft guidance describes a weightof-evidence approach to determining
whether additional immunotoxicity
testing for nonbiological
pharmaceuticals is appropriate when
the findings from standard toxicity
studies indicate signs of
immunotoxicity. The draft guidance is
intended to provide recommendations
on nonclinical testing to identify
compounds that have the potential to be
immunosuppressive and guidance on a
weight-of-evidence decision making
approach for immunotoxicity testing.
DATES: Submit written or electronic
comments on the draft guidance by
April 11, 2005. General comments on
agency guidance documents are
welcome at any time.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research (CDER), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857; or the Office of
Communication, Training and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448. The
guidance may also be obtained by mail
by calling the CBER Voice Information
System at 1–800–835–4709 or 301–827–
1800. Send one self-addressed adhesive
label to assist the office in processing
your requests. Submit written comments
on the draft guidance to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Submit electronic comments to https://
www.fda.gov/dockets/ecomments. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Kenneth L.
Hastings, Center for Drug
Evaluation and Research (HFD–
024), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–
5922.
Regarding the ICH:
Michelle Limoli, Office of
International Programs (HFG–1), Food
VerDate jul<14>2003
18:12 Feb 07, 2005
Jkt 205001
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4480.
SUPPLEMENTARY INFORMATION:
I. Background
ICH was organized to provide an
opportunity for tripartite harmonization
initiatives to be developed with input
from both regulatory and industry
representatives. FDA also seeks input
from consumer representatives and
others. ICH is concerned with
harmonization of technical
requirements for the registration of
pharmaceutical products among three
regions: The European Union, Japan,
and the United States. The six ICH
sponsors are the European Commission,
the European Federation of
Pharmaceutical Industries Associations,
the Japanese Ministry of Health, Labour,
and Welfare, the Japanese
Pharmaceutical Manufacturers
Association, CDER and CBER (FDA),
and the Pharmaceutical Research and
Manufacturers of America. The ICH
Secretariat, which coordinates the
preparation of documentation, is
provided by the International
Federation of Pharmaceutical
Manufacturers Associations.
The ICH Steering Committee includes
representatives from each of the ICH
sponsors and the IFPMA, as well as
observers from the World Health
Organization (WHO), Health Canada,
and the European Free Trade Area.
In November 2004, the ICH Steering
Committee agreed that a draft guidance
entitled ‘‘S8 Immunotoxicity Studies for
Human Pharmaceuticals’’ should be
made available for public comment. The
draft guidance is the product of the
Safety Expert Working Group of the
ICH. Comments about this draft
guidance will be considered by FDA
and the Safety Expert Working Group.
The draft guidance describes a
weight-of-evidence approach to
determining whether additional
immunotoxicity testing for
nonbiological pharmaceuticals is
appropriate when the findings from
standard toxicity studies indicate signs
of immunotoxicity. The draft guidance
provides the following: (1)
Recommendations on nonclinical
testing approaches to identify
compounds which have the potential to
be immunosuppressive and (2) guidance
on a weight-of-evidence decision
making approach for immunotoxicity
testing. The primary data are from
routine nonclinical toxicology studies
conducted during drug development.
Additional causes for concern that can
affect the decision for additional
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
immunotoxicity testing include the
pharmacology of the drug, intended
patient population, known drug class
effects, and retention of the drug in cells
of the immune system.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
This draft guidance, when finalized,
will represent the agency’s current
thinking on this topic. It does not create
or confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments on the draft guidance. Two
copies of mailed comments are to be
submitted, except that individuals may
submit one copy. Comments are to be
identified with the docket number
found in brackets in the heading of this
document. The draft guidance and
received comments may be seen in the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
III. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/ohrms/dockets/
default.htm, https://www.fda.gov/cder/
guidance/index.htm, or https://
www.fda.gov/cber/publications.htm.
Dated: February 1, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–2418 Filed 2–7–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
Program Exclusions: January 2005
AGENCY:
Office of Inspector General,
HHS.
ACTION:
Notice of program exclusions.
During the month of January 2005, the
HHS Office of Inspector General
imposed exclusions in the cases set
forth below. When an exclusion is
imposed, no program payment is made
to anyone for any items or services
(other than an emergency item or
service not provided in a hospital
emergency room) furnished, ordered or
prescribed by an excluded party under
E:\FR\FM\08FEN1.SGM
08FEN1
]]>Agencies
[Federal Register Volume 70, Number 25 (Tuesday, February 8, 2005)]
[Notices]
[Pages 6697-6698]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-2418]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D-0022]
International Conference on Harmonisation; Draft Guidance on S8
Immunotoxicity Studies for Human Pharmaceuticals; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 6698]]
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance entitled ``S8 Immunotoxicity Studies
for Human Pharmaceuticals.'' The draft guidance was prepared under the
auspices of the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH).
The draft guidance describes a weight-of-evidence approach to
determining whether additional immunotoxicity testing for nonbiological
pharmaceuticals is appropriate when the findings from standard toxicity
studies indicate signs of immunotoxicity. The draft guidance is
intended to provide recommendations on nonclinical testing to identify
compounds that have the potential to be immunosuppressive and guidance
on a weight-of-evidence decision making approach for immunotoxicity
testing.
DATES: Submit written or electronic comments on the draft guidance by
April 11, 2005. General comments on agency guidance documents are
welcome at any time.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Division of Drug Information (HFD-240), Center for Drug
Evaluation and Research (CDER), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857; or the Office of Communication,
Training and Manufacturers Assistance (HFM-40), Center for Biologics
Evaluation and Research (CBER), Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852-1448. The guidance may also be
obtained by mail by calling the CBER Voice Information System at 1-800-
835-4709 or 301-827-1800. Send one self-addressed adhesive label to
assist the office in processing your requests. Submit written comments
on the draft guidance to the Division of Dockets Management (HFA-305),
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Submit electronic comments to https://www.fda.gov/dockets/
ecomments. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Kenneth L. Hastings, Center for Drug
Evaluation and Research (HFD-024), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-5922.
Regarding the ICH:
Michelle Limoli, Office of International Programs (HFG-1), Food and
Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-
4480.
SUPPLEMENTARY INFORMATION:
I. Background
ICH was organized to provide an opportunity for tripartite
harmonization initiatives to be developed with input from both
regulatory and industry representatives. FDA also seeks input from
consumer representatives and others. ICH is concerned with
harmonization of technical requirements for the registration of
pharmaceutical products among three regions: The European Union, Japan,
and the United States. The six ICH sponsors are the European
Commission, the European Federation of Pharmaceutical Industries
Associations, the Japanese Ministry of Health, Labour, and Welfare, the
Japanese Pharmaceutical Manufacturers Association, CDER and CBER (FDA),
and the Pharmaceutical Research and Manufacturers of America. The ICH
Secretariat, which coordinates the preparation of documentation, is
provided by the International Federation of Pharmaceutical
Manufacturers Associations.
The ICH Steering Committee includes representatives from each of
the ICH sponsors and the IFPMA, as well as observers from the World
Health Organization (WHO), Health Canada, and the European Free Trade
Area.
In November 2004, the ICH Steering Committee agreed that a draft
guidance entitled ``S8 Immunotoxicity Studies for Human
Pharmaceuticals'' should be made available for public comment. The
draft guidance is the product of the Safety Expert Working Group of the
ICH. Comments about this draft guidance will be considered by FDA and
the Safety Expert Working Group.
The draft guidance describes a weight-of-evidence approach to
determining whether additional immunotoxicity testing for nonbiological
pharmaceuticals is appropriate when the findings from standard toxicity
studies indicate signs of immunotoxicity. The draft guidance provides
the following: (1) Recommendations on nonclinical testing approaches to
identify compounds which have the potential to be immunosuppressive and
(2) guidance on a weight-of-evidence decision making approach for
immunotoxicity testing. The primary data are from routine nonclinical
toxicology studies conducted during drug development. Additional causes
for concern that can affect the decision for additional immunotoxicity
testing include the pharmacology of the drug, intended patient
population, known drug class effects, and retention of the drug in
cells of the immune system.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). This draft guidance,
when finalized, will represent the agency's current thinking on this
topic. It does not create or confer any rights for or on any person and
does not operate to bind FDA or the public. An alternative approach may
be used if such approach satisfies the requirements of the applicable
statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments on the draft guidance.
Two copies of mailed comments are to be submitted, except that
individuals may submit one copy. Comments are to be identified with the
docket number found in brackets in the heading of this document. The
draft guidance and received comments may be seen in the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at
https://www.fda.gov/ohrms/dockets/default.htm, https://www.fda.gov/cder/
guidance/index.htm, or https://www.fda.gov/cber/publications.htm.
Dated: February 1, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-2418 Filed 2-7-05; 8:45 am]
BILLING CODE 4160-01-S
